The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
Open accessAbstract
Summary Passively-administered anti-tumor mAbs rapidly kill tumor targets via FcγR-mediated cytotoxicity (ADCC), a short-term process. However, anti-tumor mAb treatment can also induce a vaccinal effect, in which mAb-mediated tumor death induces a long-term anti-tumor cellular immune response. To determine how such responses are generated, we utilized a murine model of an anti-tumor vaccinal effect against a model neoantigen. We demonstrate that FcγR expression by CD11c+ antigen-presenting cells is required to generate anti-tumor T cell responses upon ADCC-mediated tumor clearance. Using FcγR-humanized mice, we demonstrate that anti-tumor huIgG1 must engage hFcγRIIIA on macrophages to mediate ADCC, but also engage hFcγRIIA, the sole hFcγR expressed by human DCs, to generate a potent vaccinal effect. Thus, while next-generation anti-tumor antibodies with enhanced binding to only hFcγRIIIA are now in clinical use, ideal anti-tumor antibodies must be optimized for both cytotoxic effects as well as hFcγRIIA engagement on DCs to stimulate long-term anti-tumor cellular immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Self-citationInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“Thus, activating FcgRs mediate the initial ADCC clearance of tumor cells by anti-tumor mAb, as reported (Clynes et al., 2000; Uchida et al., 2004).”
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Self-citationDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Self-citationMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
FcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Self-citationvan Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749
Self-citationFcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660
Self-citationUchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Self-citationThe therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Self-citationBroadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2014) · Cell · doi:10.1016/j.cell.2014.08.023 · Cited by 493
Self-citationThe half-lives of serum immunoglobulins in adult mice
Vieira, P., & Rajewsky, K. (1988) · European Journal of Immunology · doi:10.1002/eji.1830180221 · Cited by 445
Fc‐Receptors as Regulators of Immunity
Nimmerjahn, F., & Ravetch, J. V. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96005-8 · Cited by 418
Self-citationActivating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
Boruchov, A. M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24772 · Cited by 377
Kalergis, A. M., & Ravetch, J. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020338 · Cited by 372
Self-citationLi, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Self-citationMouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 307
Self-citationImmune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15640 · Cited by 266
Robbiani, D. F., Bunting, S., Feldhahn, N., Bothmer, A., Camps, J., Deroubaix, S., McBride, K. M., Klein, I. A., Stone, G., Eisenreich, T. R., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.11.007 · Cited by 261
Dhodapkar, K. M., Kaufman, J. L., Ehlers, M., Banerjee, D. K., Bonvini, E., Koenig, S., Steinman, R. M., Ravetch, J. V., & Dhodapkar, M. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500014102 · Cited by 241
Self-citationSeidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215640 · Cited by 232
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies
Abu-Shakra, M., Buskila, D., Ehrenfeld, M., Conrad, K., & Shoenfeld, Y. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.5.433 · Cited by 227
Mayer, C. T., Ghorbani, P., Nandan, A., Dudek, M., Arnold-Schrauf, C., Hesse, C., Berod, L., Stüve, P., Puttur, F., Merad, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-545772 · Cited by 219
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Taylor, C., Hershman, D., Shah, N., Suciu-Foca, N., Petrylak, D. P., Taub, R., Vahdat, L., Cheng, B., Pegram, M., Knutson, K. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0507 · Cited by 213
McKenzie, S. E., Taylor, S. M., Malladi, P., Yuhan, H., Cassel, D. L., Chien, P., Schwartz, E., Schreiber, A. D., Surrey, S., & Reilly, M. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.4311 · Cited by 208
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
Nimmerjahn, F., Lux, A., Albert, H., Woigk, M., Lehmann, C., Dudziak, D., Smith, P., & Ravetch, J. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014515107 · Cited by 200
Self-citationLong-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Abès, R., Gélizé, E., Fridman, W. H., & Teillaud, J.-L. (2010) · Blood · doi:10.1182/blood-2009-10-248609 · Cited by 198
McKenzie, S. E., Taylor, S. M., Malladi, P., et al. (1999) · PubMed · Cited by 184
Nimmerjahn, F., & Ravetch, J. V. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_86 · Cited by 180
Self-citationHilchey, S. P., Hyrien, O., Mosmann, T. R., Livingstone, A. M., Friedberg, J. W., Young, F. M., Fisher, R. I., Kelleher, R. J., Bankert, R. B., & Bernstein, S. H. (2009) · Blood · doi:10.1182/blood-2008-10-185280 · Cited by 156
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
Taylor, R. P., & Lindorfer, M. A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.011 · Cited by 155
In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
de Haij, S., Jansen, J. H. M., Boross, P., Beurskens, F. J. M., Bakema, J. E., Bos, D. L., Martens, A. C., Verbeek, J. S., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4109 · Cited by 130
Otten, M. A., van der Bij, G. J., Verbeek, S. J., Nimmerjahn, F., Ravetch, J. V., Beelen, R. H. J., van de Winkel, J. G. J., & van Egmond, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6829 · Cited by 89
Self-citationCross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies?
Selenko-Gebauer, N., Majdic, O., Jaeger, U., Sillaber, C., Stöckl, J., & Knapp, W. (2002) · Journal of Clinical Immunology · doi:10.1023/a:1015463811683 · Cited by 69
Berlyn, K. A., Schultes, B. C., Leveugle, B., Noujaim, A. A., Alexander, R. B., & Mann, D. L. (2001) · Clinical Immunology · doi:10.1006/clim.2001.5115 · Cited by 66
Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice.
Li, M. Y., Wirthmueller, U., & Ravetch, J. V. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.3.1259 · Cited by 65
Self-citationPersonal neoantigen cancer vaccines
Fritsch, E. F., Hacohen, N., & Wu, C. J. (2014) · OncoImmunology · doi:10.4161/onci.29311 · Cited by 61
Humanized Mice to Study FcγR Function
Bournazos, S., DiLillo, D. J., & Ravetch, J. V. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_11 · Cited by 39
Self-citation
Cited by
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Metadata
- Authors
- DiLillo, D. J., & Ravetch, J. V.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1035-1045
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W1495576644
- Cited by
- 266
- References
- 51
- FWCI
- 22.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.